Cargando…

Comparative oncology approach to drug repurposing in osteosarcoma

BACKGROUND: Osteosarcoma is an orphan disease for which little improvement in survival has been made since the late 1980s. New drug discovery for orphan diseases is limited by the cost and time it takes to develop new drugs. Repurposing already approved FDA-drugs can help overcome this limitation. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parrales, Alejandro, McDonald, Peter, Ottomeyer, Megan, Roy, Anuradha, Shoenen, Frank J., Broward, Melinda, Bruns, Tyce, Thamm, Douglas H., Weir, Scott J., Neville, Kathleen A., Iwakuma, Tomoo, Fulbright, Joy M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868798/ https://www.ncbi.nlm.nih.gov/pubmed/29579058 http://dx.doi.org/10.1371/journal.pone.0194224

Ejemplares similares

Targeting Oncogenic Mutant p53 for Cancer Therapy
por: Parrales, Alejandro, et al.
Publicado: (2015)

p53 as a Regulator of Lipid Metabolism in Cancer
por: Parrales, Alejandro, et al.
Publicado: (2016)

Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression
por: Iyer, Swathi V., et al.
Publicado: (2016)

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities
por: Iyer, Swathi V., et al.
Publicado: (2015)

Suppressing STAT5 signaling affects osteosarcoma growth and stemness
por: Subramaniam, Dharmalingam, et al.
Publicado: (2020)

DNAJA1- and conformational mutant p53-dependent inhibition of cancer cell migration by a novel compound identified through a virtual screen
por: Nishikawa, Shigeto, et al.
Publicado: (2022)

Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin
por: Alalem, Mohamed, et al.
Publicado: (2022)

Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma
por: Kundu, Anup K., et al.
Publicado: (2017)

Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation
por: Polireddy, Kishore, et al.
Publicado: (2016)

Oncology Drug Repurposing for Sepsis Treatment
por: Rumienczyk, Izabela, et al.
Publicado: (2022)

Repurposing Drugs in Small Animal Oncology
por: Giuliano, Antonio, et al.
Publicado: (2022)

The Role of Dopamine in Repurposing Drugs for Oncology
por: Moura, Catarina, et al.
Publicado: (2023)

Prediction and Identification of GPCRs Targeting for Drug Repurposing in Osteosarcoma
por: Tan, Manli, et al.
Publicado: (2022)

Non-Canonical Cell Death Induced by p53
por: Ranjan, Atul, et al.
Publicado: (2016)

Roles of p53 in extrinsic factor-induced liver carcinogenesis
por: Link, Tim, et al.
Publicado: (2017)

Emerging Non-Canonical Functions and Regulation of p53
por: Ranjan, Atul, et al.
Publicado: (2018)

Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)

Regulation of p53 and Cancer Signaling by Heat Shock Protein 40/J-Domain Protein Family Members
por: Kaida, Atsushi, et al.
Publicado: (2021)

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
por: Nishikawa, Shigeto, et al.
Publicado: (2023)

Repurposing Avasimibe to Inhibit Bacterial Glycosyltransferases
por: Hasan, Md Kamrul, et al.
Publicado: (2022)

A novel link between the HER2-Akt and MDM2-p53 pathways via CSN6
por: Iyer, Swathi V., et al.
Publicado: (2012)

A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing
por: Cabrera-Andrade, Alejandro, et al.
Publicado: (2020)

The Repurposing Drugs in Oncology (ReDO) Project
por: Pantziarka, Pan, et al.
Publicado: (2014)

Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway
por: Busso, Carlos S., et al.
Publicado: (2009)

Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis
por: Ranjan, Atul, et al.
Publicado: (2016)

Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
por: Araki, Wataru
Publicado: (2013)

“Hard” Drug Repurposing for Precision Oncology: The Missing Link?
por: Pantziarka, Pan, et al.
Publicado: (2018)

ReDO_DB: the repurposing drugs in oncology database
por: Pantziarka, Pan, et al.
Publicado: (2018)

A Database of Drug Repurposing Clinical Trials in Oncology
por: Pantziarka, Pan, et al.
Publicado: (2021)

Validation of transcriptome signature reversion for drug repurposing in oncology
por: Koudijs, Karel K M, et al.
Publicado: (2022)

Perinucleolar Compartment (PNC) Prevalence as an Independent Prognostic Factor in Pediatric Ewing Sarcoma: A Multi-Institutional Study
por: Gonzalez, Elizabeth, et al.
Publicado: (2023)

Oncological and functional outcome of periosteal osteosarcoma
por: Gulia, Ashish, et al.
Publicado: (2014)

Review of Cardiotoxicity in Pediatric Cancer Patients: During and after Therapy
por: Fulbright, Joy M.
Publicado: (2011)

The perplexing role of immuno-oncology drugs in osteosarcoma
por: Smrke, Alannah, et al.
Publicado: (2021)

Improving Osteosarcoma Treatment: Comparative Oncology in Action
por: Tarone, Lidia, et al.
Publicado: (2022)

Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma
por: Sobol, Natasha Tatiana, et al.
Publicado: (2021)

Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014)

Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2015)

Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2016)

Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_95ggf193isphebmce8e0pfuoff